Combination active in advanced classic Hodgkin lymphoma
The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared promising for adults with bulky stage II or stage III/stage IV classic Hodgkin lymphoma, according to study results.
Nearly all (93%) patients treated with the combination responded to therapy and 88% achieved complete response, results of a multicenter phase 2 study presented at ASH Annual Meeting and Exposition showed.
The regimen exhibited a manageable toxicity profile, according to investigators.
Researcher Mitul Gandhi, MD, hematologist and oncologist at Virginia Cancer Specialists — part of US Oncology Network — spoke with Healio about the study results and their potential implications.
Collapse
Lee H, et al. Abstract 314. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Read more about